On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of improvement in response rates, although the company did not give detailed data in its announcement. SymBio guided toward submission of the data to the PMDA in H120 and we expect initial sales in 2021, driving sustained profitability.
05 Dec 2019
SymBio Pharmaceuticals - Treakisym has positive DLBCL results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SymBio Pharmaceuticals - Treakisym has positive DLBCL results
Symbio Pharmaceuticals Limited (4582:TKS) | 0 0 0.0%
- Published:
05 Dec 2019 -
Author:
Dr Nathaniel Calloway -
Pages:
7
On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of improvement in response rates, although the company did not give detailed data in its announcement. SymBio guided toward submission of the data to the PMDA in H120 and we expect initial sales in 2021, driving sustained profitability.